Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Choueiri, Toni K; Escudier, Bernard; Powles, Thomas; Mainwaring, Paul N; Rini, Brian I; Donskov, Frede; Hammers, Hans; Hutson, Thomas E; Lee, Jae-Lyun; Peltola, Katriina; Roth, Bruce J; Bjarnason, Georg A; Géczi, Lajos; Keam, Bhumsuk; Maroto, Pablo; Heng, Daniel YC; Schmidinger, Manuela; Kantoff, Philip W; Borgman-Hagey, Anne; Hessel, Colin; Scheffold, Christian; Schwab, Gisela M; Tannir, Nizar M; Motzer, Robert J; METEOR Investigators,

doi:10.1056/NEJMoa1510016

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Author:

Choueiri, Toni K

Escudier, Bernard ; Powles, Thomas ; Mainwaring, Paul N ; Rini, Brian I ; Donskov, Frede ; Hammers, Hans ; Hutson, Thomas E ; Lee, Jae-Lyun ; Peltola, Katriina ; Roth, Bruce J ; Bjarnason, Georg A ; Géczi, Lajos ; Keam, Bhumsuk ; Maroto, Pablo ; Heng, Daniel YC ; Schmidinger, Manuela ; Kantoff, Philip W ; Borgman-Hagey, Anne ; Hessel, Colin ; Scheffold, Christian ; Schwab, Gisela M ; Tannir, Nizar M ; Motzer, Robert J ; METEOR Investigators,

Keywords:

Adult, Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Carcinoma, Renal Cell, Disease-Free Survival, Everolimus, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Pyridines, Quality of Life, Sirolimus, Survival Analysis, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, PHASE-III TRIAL, PROGNOSTIC-FACTORS, HGF/C-MET, C-MET, SUNITINIB, TUMORS, METASTASIS, XL184, NEPHRECTOMY, SORAFENIB, METEOR Investigators, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.